A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
Public ClinicalTrials.gov record NCT06616974. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)
Study identification
- NCT ID
- NCT06616974
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Tectonic Therapeutic
- Industry
- Enrollment
- 191 participants
Conditions and interventions
Interventions
- TX000045- Dose A Drug
- TX000045- Dose B Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 83 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 3, 2024
- Primary completion
- Nov 23, 2026
- Completion
- Jan 4, 2027
- Last update posted
- Jul 6, 2026
2024 – 2027
United States locations
- U.S. sites
- 25
- U.S. states
- 18
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenix | Phoenix | Arizona | 85283 | — |
| Scottsdale | Scottsdale | Arizona | 85258 | — |
| San Francisco | San Francisco | California | 94143 | — |
| Santa Rosa | Santa Rosa | California | 95405 | — |
| Aurora | Aurora | Colorado | 80045 | — |
| Jacksonville | Jacksonville | Florida | 32216 | — |
| Augusta | Augusta | Georgia | 30912 | — |
| McDonough | McDonough | Georgia | 30253 | — |
| Boise | Boise | Idaho | 83706 | — |
| USA | Louisville | Kentucky | 40202 | — |
| Baltimore | Baltimore | Maryland | 21201 | — |
| Boston | Boston | Massachusetts | 02180 | — |
| Minneapolis | Minneapolis | Minnesota | 55414 | — |
| St Louis | St Louis | Missouri | 63110 | — |
| Omaha | Omaha | Nebraska | 68198 | — |
| New York | New York | New York | 10029 | — |
| New York | New York | New York | 10075 | — |
| Durham | Durham | North Carolina | 27710 | — |
| Philadelphia | Philadelphia | Pennsylvania | 19107 | — |
| Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| York | York | Pennsylvania | 17403 | — |
| Port Arthur | Port Arthur | Texas | 77642 | — |
| Waco | Waco | Texas | 76712 | — |
| Salt Lake City | Salt Lake City | Utah | 84112 | — |
| United States | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06616974, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 6, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06616974 live on ClinicalTrials.gov.